Caldwell Sutter Capital Inc. Grows Stake in Kenvue Inc. (NYSE:KVUE)

Caldwell Sutter Capital Inc. boosted its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 4.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 24,656 shares of the company’s stock after buying an additional 1,042 shares during the period. Caldwell Sutter Capital Inc.’s holdings in Kenvue were worth $526,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Grove Bank & Trust raised its stake in Kenvue by 438.4% in the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company’s stock valued at $25,000 after purchasing an additional 947 shares in the last quarter. Riverview Trust Co bought a new stake in shares of Kenvue during the 3rd quarter worth $30,000. Fortitude Family Office LLC grew its position in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company’s stock worth $32,000 after acquiring an additional 777 shares in the last quarter. Ashton Thomas Securities LLC bought a new position in Kenvue in the third quarter valued at $35,000. Finally, Versant Capital Management Inc raised its position in Kenvue by 300.8% during the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company’s stock valued at $41,000 after purchasing an additional 1,441 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on KVUE shares. UBS Group cut their price objective on Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday, January 16th. Bank of America raised their price objective on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research note on Tuesday, October 22nd. Royal Bank of Canada upgraded Kenvue from a “hold” rating to a “moderate buy” rating in a report on Monday, December 9th. Piper Sandler raised Kenvue from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $21.00 to $26.00 in a research note on Monday, January 6th. Finally, Citigroup dropped their price objective on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Kenvue has an average rating of “Hold” and an average price target of $23.08.

Kenvue Stock Down 0.0 %

Shares of Kenvue stock opened at $20.75 on Friday. The company has a 50-day simple moving average of $22.26 and a two-hundred day simple moving average of $21.74. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. The stock has a market capitalization of $39.77 billion, a PE ratio of 37.72, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The business had revenue of $3.90 billion for the quarter, compared to analysts’ expectations of $3.92 billion. The firm’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the prior year, the firm posted $0.31 EPS. On average, analysts anticipate that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date of this dividend is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.95%. Kenvue’s payout ratio is 149.09%.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.